文献速递细菌感染、耐药与抗菌药物医院感染防控

英国和爱尔兰革兰阳性菌血流感染耐药趋势:2001至2019年

Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

BSAC血流感染耐药监测与UKHSA监测数据对比显示,2001至2019年MRSA血流分离率从约40%降至10%以下,但夫西地酸耐药上升,屎肠球菌对万古霉素耐药平均29%,多耐药屎肠球菌心内膜炎治疗选择有限。

要点

  • MRSA血流分离率从2001年约40%降至2019年<10%
  • 屎肠球菌万古霉素耐药平均29%,粪肠球菌仅2%
  • 噁唑烷酮类、替加环素、达托霉素和抗PBP2'头孢菌素对靶菌几乎全部保持活性

核心结论

  • 革兰阳性菌曾是血流感染主要病原体,监测显示多种抗生素近乎普遍有效,该局面重现风险低。
  • 部分场景治疗选择有限,尤其是多耐药屎肠球菌心内膜炎。

研究设计与样本

  • BSAC血流感染耐药监测每年按站点配额收集英国和爱尔兰医院分离株,2001至2019年用琼脂稀释法测MIC,协同试验、解释性读数和PCR鉴定耐药机制。
  • UKHSA监测收集英格兰医院所有血流分离株的药敏数据。
  • 两套监测结果汇总比较。

主要发现

  • 两套系统均记录MRSA从2001年约40%的血流金黄色葡萄球菌降至2019年<10%。
  • MRSA(尤其)和MSSA对夫西地酸耐药比例上升,MRSA对环丙沙星和大环内酯类耐药下降。
  • 凝固酶阴性葡萄球菌甲氧西林耐药仅小幅下降,夫西地酸耐药上升。
  • 肺炎链球菌耐药率保持低位,高剂量青霉素几乎普遍有效,变化反映疫苗相关血清型替换。
  • 屎肠球菌相对粪肠球菌更常见,万古霉素耐药在屎肠球菌平均29%、粪肠球菌2%,无趋势。

关键数值与推荐

  • MRSA血流分离率从2001年约40%降至2019年<10%。
  • 屎肠球菌万古霉素耐药平均29%,粪肠球菌2%,无趋势。

临床怎么用

  • 经验性治疗革兰阳性血流感染时,噁唑烷酮类、达托霉素和抗PBP2'头孢菌素仍可覆盖多数靶菌。
  • 多耐药屎肠球菌心内膜炎治疗选择有限,需关注万古霉素耐药率约29%。
  • 夫西地酸耐药上升,不宜单凭既往经验用于葡萄球菌血流感染。

局限性

  • BSAC为配额采样,UKHSA为医院自报数据,两套系统方法不同。
  • 原文未报告样本量、置信区间和P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The BSAC Bacteraemia Resistance Surveillance collected isolates from UK and Irish hospitals for central testing. Concurrent UKHSA surveillance collated English hospitals' own susceptibility data. Results were collated and compared. METHODS: BSAC Surveillance collected quotas of isolates per site annually from 2001 to 2019. MIC testing was by BSAC agar dilution, with resistance mechanisms identified by synergy tests, interpretive reading and PCR. The UKHSA sought hospitals' data on all bacteraemia isolates. RESULTS: Both surveillance systems recorded dramatic falls in MRSA, from c. 40% of bloodstream Staphylococcus aureus in 2001 to <10% by 2019. Both noted rises in the proportion of MRSA (especially) and MSSA resistant to fusidic acid, along with declines of ciprofloxacin and macrolide resistance amongst MRSA. Methicillin resistance also fell among coagulase-negative staphylococci, albeit only modestly; fusidic acid resistance rose. Shifts for pneumococci were complex, reflecting vaccine-contingent serotype displacements; resistance rates remained low, with high-dose penicillin almost universally active. Enterococcus faecium became more prevalent relative to Enterococcus faecalis; vancomycin resistance averaged 29% among E. faecium versus 2% in E. faecalis, without trend. Erythromycin resistance rose among groups B, C and G (but not group A) streptococci. Oxazolidinones, tigecycline, daptomycin and anti-PBP2' cephalosporins retained near-universal activity against target species, except that tigecycline has been compromised by breakpoint reductions for streptococci. CONCLUSIONS: Gram-positive pathogens were the dominant historical pathogens of bacteraemia. The trends seen here-with many near-universally active antibiotics-indicate little hazard of this situation returning. Nevertheless, few treatments exist in some settings, notably multi-resistant E. faecium endocarditis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Reynolds R, Mushtaq S, Hope R, et al. Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019. J Antimicrob Chemother. 2025. PMID: 41140273. doi:10.1093/jac/dkaf249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。